Inhaled aspirin and magnesium to treat inflammation
A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 μm to about 5 μm. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
1. A method of treating an inflammatory condition in a subject in need thereof, comprising administering via the respiratory tract of the subject a dry powder composition comprising:
dry particles comprising acetylsalicylic acid (ASA), or a pharmaceutically acceptable salt thereof, co-micronized with a magnesium stearate, wherein the magnesium stearate is in an amount of about 0.05% (w/w) or about 0.5% (w/w) of the dry powder composition, and wherein ASA stability maintains 95% or above after exposure to a condition selected from the group consisting of 15-20° C./35-45% relative humidity (RH), 20° C./40% RH, 30° C./60% RH, 40° C./75% RH, and 50° C./75% RH, for two weeks, four weeks, 30 days, a month, six weeks, eight weeks, or 12 months.
2. The method of claim 1 , wherein the magnesium stearate is in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the dry powder composition, wherein acetylsalicylic acid, or a pharmaceutically acceptable salt thereof, is in an amount of about 50% (w/w) or more of the dry powder composition.
3. The method of claim 1 , wherein the dry powder composition is substantially free of carrier particles.
4. The method of claim 1 , wherein the dry particles have a median mass aerodynamic diameter (MMAD) MMAD within a range of about 1 μm to about 5 μm.
5. The method of claim 4 , wherein the dry particles have a MMAD within a range of about 2 μm to about 3 μm.
6. The method of claim 4 , wherein the MMAD of the dry particles varies by less than about 10% after the dry powder composition have been stored at 50° C./75% relative humidity for about 5 days when compared with the MMAD at time, t, equals zero.
7. The method of claim 4 , wherein the dry particles have an MMAD size distribution with a DV90 less than about 6 μm, a DV50 less than about 3 μm, and a DV10 less than about 1 μm.
8. The method of claim 1 , wherein acetylsalicylic acid, or a pharmaceutically acceptable salt thereof, is in an amount of about 80% (w/w) or more of the dry powder composition.
9. The method of claim 1 , wherein the aerodynamic particle size distribution (APSD) of the dry powder composition as measured by mass deposition at stage 1 to stage 8 of a Next Generation Impactor (NGI) varies by less than about 10% after the dry powder composition have been stored at 50° C./75% relative humidity for about 30 days when compared with the APSD at time, t, equals zero.
10. The method of claim 9 , wherein the DV90, DV50 and/or DV10 vary less than about 10% after the composition is stored at 50° C./75% relative humidity for about 15 days.
11. The method of claim 1 , wherein the inflammatory condition is selected from the group consisting of cancer, chronic obstructive pulmonary disease (COPD), arthritis, and an autoimmune disorder.
12. A method of treating an inflammatory condition in a subject in need thereof, comprising using a drug delivery system to administer a dry powder composition via the respiratory tract of the subject, wherein said drug delivery system comprises:
dry particles comprising acetylsalicylic acid (ASA), or a pharmaceutically acceptable salt thereof, co-micronized with a magnesium stearate, wherein the magnesium stearate is in an amount of about 0.05% (w/w) or about 0.5% (w/w) of the dry powder composition, and wherein ASA stability maintains 95% or above after exposure to a condition selected from the group consisting of 15-20° C./35-45% relative humidity (RH), 20° C./40% RH, 30° C./60% RH, 40° C./75% RH, and 50° C./75% RH, for two weeks, four weeks, 30 days, a month, six weeks, eight weeks, or 12 months.
13. The method of claim 12 , wherein the magnesium stearate is in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the dry powder composition, wherein acetylsalicylic acid, or a pharmaceutically acceptable salt thereof, is in an amount of about 50% (w/w) or more of the dry powder composition.
14. The method of claim 12 , wherein the dry powder composition is substantially free of carrier particles.
15. The method of claim 12 , wherein the dry particles have a median mass aerodynamic diameter (MMAD) within a range of about 1 μm to about 5 μm.
16. The method of claim 15 , wherein the dry particles have a MMAD within a range of about 2 μm to about 3 μm.
17. The method of claim 15 , wherein the MMAD of the dry particles varies by less than about 10% after the dry powder composition have been stored at 50° C./75% relative humidity for about 5 days when compared with the MMAD at time, t, equals zero.
18. The method of claim 15 , wherein the dry particles have an MMAD size distribution with a DV90 less than about 6 μm, a DV50 less than about 3 μm, and a DV10 less than about 1 μm.
19. The method of claim 12 , wherein acetylsalicylic acid, or a pharmaceutically acceptable salt thereof, is in an amount of about 80% (w/w) or more of the dry powder composition.
20. The method of claim 12 , wherein the aerodynamic particle size distribution (APSD) of the dry powder composition as measured by mass deposition at stage 1 to stage 8 of a Next Generation Impactor (NGI) varies by less than about 10% after the dry powder composition have been stored at 50° C./75% relative humidity for about 30 days when compared with the APSD at time, t, equals zero.
21. The method of claim 20 , wherein the DV90, DV50 and/or DV10 vary less than about 10% after the composition is stored at 50° C./75% relative humidity for about 15 days.
22. The method of claim 12 , wherein the inflammatory condition is selected from the group consisting of cancer, chronic obstructive pulmonary disease (COPD), arthritis, and an autoimmune disorder.
23. The method of claim 12 , wherein the drug delivery system further comprises clopidogrel.
24. The method of claim 12 , wherein the drug delivery system comprises a dry powder inhaler and the dry powder composition.
25. The method of claim 12 , wherein the dry powder inhaler comprises:
a housing defining a chamber having one or more air inlets, and one or more air outlets;
the chamber sized to receive a capsule which contains the dry powder composition;
a puncturing mechanism in the housing for creating one or more openings in the capsule;
an optional shield covering at least two but not all of the air inlets, wherein the optional shield comprises one or two or more covering portions, each covering portion covering at least one inlet, whereby the optional shield prevents blockage of at least two air inlets by a user grasping the apparatus; and
an end section associated with the housing, the end section sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to aerosolize the dry powder composition and to inhale aerosolized dry powder composition that has exited the capsule.